This genetically engineered mouse model harnesses CRISPR/Cas-9 technology to introduce a precise single nucleotide mutation in the ADAR1 gene, resulting in a lysine-to-asparagine substitution. The process involves injecting a custom-designed guide RNA alongside template DNA into mouse zygotes, followed by embryo transfer and rigorous progeny screening via DNA sequencing. The model exhibits elevated type I interferon levels and spontaneous brain inflammation, effectively mirroring key neuroinflammatory features characteristic of Aicardi-Goutières syndrome. These attributes provide researchers with a robust tool for studying complex neuroimmune interactions in vivo.